Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07777029

Subcutaneous Methadone for Cesarean Analgesia: a Non Inferiority Study Using QoR-10

This study aims to evaluate whether subcutaneous methadone provides postoperative analgesia that is non-inferior to that achieved with intrathecal morphine in women undergoing cesarean delivery under neuraxial anesthesia. The primary outcome will be the quality of postoperative recovery, assessed using the QoR-10 score during the first 24 hours after surgery. Secondary outcomes will include postoperative pain intensity, opioid consumption, incidence of adverse effects, and maternal satisfaction.

This trial seeks to determine whether subcutaneous methadone could represent an alternative analgesic strategy within multimodal analgesia protocols for cesarean delivery.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

About this study

Effective postoperative analgesia following cesarean delivery is a fundamental component of maternal recovery and patient satisfaction. Current international recommendations, including the most recent 2026 update from the PROSPECT Working Group, emphasize that neuraxial morphine remains the gold standard for postoperative analgesia. These guidelines also highlight the strong evidence supporting multimodal analgesia strategies, including the routine use of paracetamol and dexamethasone as adjuncts to improve analgesic outcomes and postoperative recovery.

Despite its efficacy, intrathecal morphine may be associated with dose-dependent adverse effects, such as pruritus, nausea, vomiting, and respiratory depression. For this reason, there remains ongoing clinical interest in identifying alternative analgesic strategies that provide comparable efficacy with a more favorable safety profile.

Methadone is a long-acting opioid that also exhibits N-methyl-D-aspartate (NMDA) receptor antagonist properties, which may enhance analgesia and reduce postoperative opioid requirements. There is evidence supporting its use in cesarean delivery when administered intravenously. In particular, a randomized trial demonstrated that intravenous methadone provides effective postoperative analgesia following cesarean delivery. However, other routes of administration have not been adequately evaluated in this setting.

The subcutaneous route may offer several potential advantages, including ease of administration, predictable absorption, and sustained systemic drug exposure, which could make it a practical alternative in obstetric analgesia. To date, subcutaneous methadone has not been evaluated nor directly compared with intrathecal morphine, which remains the current standard for post-cesarean analgesia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women aged 18-45 years
  • Singleton pregnancy at term (≥37 weeks of gestation)
  • Scheduled for elective cesarean delivery
  • Planned neuraxial spinal anesthesia
  • Ability to understand and complete the QoR-10 questionnaire
  • Provision of written informed consent

Exclusion criteria

  • Emergency cesarean delivery
  • Contraindication to neuraxial anesthesia
  • Known hypersensitivity or allergy to methadone or morphine
  • Chronic opioid use or opioid dependence

Treatment and study plan

Methadone 0.15 mg/kg

Drug

Subcutaneous methadone administered for postoperative analgesia following cesarean delivery under neuraxial anesthesia.

Morphine

Drug

Intrathecal morphine administered during neuraxial anesthesia for postoperative analgesia following cesarean delivery.

Primary outcomes

  1. Quality of Recovery-10 (QoR-10) score at 24 hours

    Time frame: 24 hours

    cesarean delivery. The QoR-10 is a validated patient-reported outcome measure ranging from 0 to 100, with higher scores indicating better recovery. The study is designed to assess noninferiority of subcutaneous methadone compared to intrathecal morphine using a predefined noninferiority margin of 8 points.

Secondary outcomes

  1. Postoperative pain intensity

    Time frame: Up to 24 hours after surgery

    Pain intensity measured using a numerical rating scale (0-10) at rest and during movement.

  2. Opioid consumption

    Time frame: Up to 24 hours after surgery

    Total opioid consumtion within the first 24 hours after cesarean section, converted to morphine oral equivalents

  3. adverse effects

    Time frame: 24 hours

    incidence of nausea, vomiting, pruritus, somnolence, respiratory deppresion within 24 hours

Study contacts

Contact information is provided by the study sponsor or research team.

JAVIERA VARGAS, MD, MSc

CONTACT

[email protected]

+56957383772

Sponsors and collaborators

Lead sponsor

Clinica Alemana de Santiago

Other

Registry information

Official study title

Subcutaneous Methadone for Cesarean Analgesia: A Non-inferiority Study Using Quality of Recovery -10 Score.

Acronym: SC-METH-CES

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Aug 20, 2026
Registry last updated
Aug 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.